Navigation Links
Implications of Statin Therapy in Bladder Cancer Patients

Smoking is one of the major risk factors for the development of bladder cancer and is also associated with cardiac disease, hyperlipidemia, and atherosclerosis.//

Consequently, it is not uncommon for patients with bladder cancer to have concomitant cardiac disease and hyperlipidemia. The 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used in the treatment of hyperlipidemia and, in fact are available as over the counter drugs in some countries due to a perceived significant impact on overall mortality from cardiac disease.

In the January issue of the New England Journal of Medicine, Hoffmann and colleagues reported on a series of patients with bladder cancer who were treated with BCG. Of the 84 patients, 19 were also receiving statin therapy. After a median follow-up of 46 months, it appeared that patients receiving statin therapy had a higher incidence of disease progression (10 of 19 (53%) versus 12 of 65 (18%), p = 0.004). The number of recurrences did not differ significantly between the groups. While a larger number of patients on statin therapy underwent radical cystectomy, among the patients who underwent radical cystectomy, the number in whom metastases developed and the time to their development were similar in the two groups. The authors concluded that 'Our observations suggest that the discontinuation of statin therapy during BCG immunotherapy might improve the clinical outcome'.

In the March issue of NEJM, Kamat and Wu reported on the outcomes of a cohort of 156 patients who received BCG treatment; 39 took statins during BCG, and 117 did not. After a median follow-up: 56 months, there was no difference in recurrences (59% in both groups, p = 0.801), tumor progression (30% vs. 28%, p = 0.57) or deaths. Furthermore, there was no difference in outcomes, even when accounting for whether patients received only induction BCG therapy or induction BCG plus maintenance therapy.


'"/>




Page: 1 2

Related medicine news :

1. Genetic Eye Disorder Can Have Other Implications
2. New Way to Open Cellular Ion Channels, Implications for Drug Design
3. Statins reduce heart attacks
4. Statins reduce risks for angioplasty patients
5. Statins Found To Be Helpful For Patients With Arthritis
6. Long-Term Benefits Of Statins Questioned
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Use of Statin can help in recovery from stroke
9. Statins Not Effective In Treating Calcific Aortic Stenosis
10. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
11. The Effects of Statins Questioned
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...arch that was published in Nature, certain genetic...dworm Caenorhabditis// elegans also decrease the g...nderstand why cancer risk increases as we grow old...or cancer therapeutics. Professor Cynthia Kenyon ...
... Andaman and Nicobar Islands who lost their parent...et to get over their trauma, says a new report.// ...committee comprising researchers Shivani Chaudhary...large number of children continue to suffer becaus...
...e University of Florida (UF) have shown that ordin... is of self-renewal //and adaptability normally as...e UF's McKnight Brain Institute in their writing, ...Development, explained in detail as to how they us...
...eek send education material on informed financial ...de in an effort to encourage// greater openness be...dical care and procedures. Informed financial cons...f time of the medical fee they have to pay, as wel...
Other Medicine News:Health News:Long-life genes - A new way to combat cancer… 2Health News:Long-life genes - A new way to combat cancer… 3Health News:Post-tsunami trauma still haunts children 2Health News:Human Brain Cells Might Have The Self Potential For Healing 2Health News:Human Brain Cells Might Have The Self Potential For Healing 3Health News:AMA Urges Doctors to be Upfront about Fees 2
(Date:9/3/2008)...G, Md., Sept. 3 /- Panacea Pharmaceut...atent Number 7,413,737 covering,antibodies against...AH), a,proprietary human cancer biomarker and ther... collaboration with the Massachusetts Institute of...wide rights to this patent,for development of huma...
(Date:9/3/2008)... Trial Reconfirms Strong Evidence Pycnogenol(R) Lo...ffect on Joints Following Cessation .... 3 /- According to the Center for,Di...on type of arthritis,is on the rise. A new study ...search, reveals Pycnogenol(R), bark extract from t...
(Date:9/2/2008)...ember 3 /-, - This Analysi...e Risk,of Stroke by 34% in Patients With Atrial Fi...eated by Antithrombotic Therapy, The results of a...dy,were presented today at the clinical trial upda...ongress 2008, in Munich, Germany. Previous results...
(Date:9/2/2008)...y Meets Primary Bone Mineral Density and Secondary... Company to Host Conference Call and Webcast Wedn...0 am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewsw...sdaq: NBIX ) today announced positive safety and ...trial using its proprietary, orally-active,nonpept...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6Reflecting on the social implications of human genetics research past present and future 2780 1Reflecting on the social implications of human genetics research past present and future 2780 2Analysis Highlights Economic Contribution of Hospitals to Communities 16090 1Analysis Highlights Economic Contribution of Hospitals to Communities 16090 2Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 1Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 2VA Announces SGLI and VGLI Premium Reductions 16086 1VA Announces SGLI and VGLI Premium Reductions 16086 2
...nistration show potential for,new option to improv...07 /PRNewswire-FirstCall/ -- Millennium,Pharmaceut...sitive,data for VELCADE, the market-leading therap... received at least one prior therapy.,These data i...ous,(SC) administration of VELCADE, a new option u...
...llicular Lymphoma Reported,Today at ASCO Annual Me... GlaxoSmithKline plc,announced today long-term eff...eek course of frontline treatment with the BEXXAR(...31 Tositumomab) in,76 patients with newly diagnose.... This regimen was found to induce durable clinica...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
Foraminotomy Kerrison Rongeurs
Synovectomy Rongeur
Fried Rongeurs
Tiemann Double Action 6" Bone Rongeur
Medicine Products: